COYA Stock Recent News

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the publication of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neur.

Coya Therapeutics is set to initiate a Phase 2 trial in ALS and release the topline results of a Phase 2 trial in Alzheimer's disease in the summer. The company's anti-inflammatory approach has received strong external validation. Recently, small open-label clinical trials in ALS and Alzheimer's have shown improvement or disease stabilization.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neuro.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that MSCI has selected the Company's shares for inclusion in its MSCI USA Micro Cap Index at the market close of May 31, 2024. The MSCI USA Micro Cap Index is designed to measure the performance of the micro cap segment of the U.S. equity market and is comprised of over 1,100 const.

Coya Therapeutics (COYA) is a clinical-stage company focused on developing multi-modality Treg therapies. CEO Howard Berman joins Nicole Petallides to give an overview of the company.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the completion of a randomized, double-blind, placebo-controlled Phase 2 study of LD IL-2 in patients with mild-to-moderate AD. The study is being conducted by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital and is funded by the Gates Foundation and the Alzheim.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the Alzheimer's Drug Discovery Foundation (“ADDF”) has purchased 603,136 shares of the Company's common stock at a purchase price of $8.29 per share for an aggregate investment of $5 million. The ADDF's mission is to rapidly accelerate the development of drugs to prevent, trea.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on Apr.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, announced that Dr. Phil Campbell, Professor of Biomedical Engineering at CMU, will discuss novel proof of concept data in his presentation, “Rapid Functionalization of Treg Exosomes for Targeted Immunotherapy” at the 5th Exosome Based Therapeutic Deve.

Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could potentially be the best drug on the market, halting ALS disease progression. Coya's shares appear undervalued based on simplified valuation methods (risk-adjusted, discounted peak sales multiple).